Background Treatment with the direct thrombin inhibitor bivalirudin, as compared with
heparin plus glycoprotein IIb/IIIa inhibitors, results in similar suppression of ischemia while …

Background Current guidelines for patients with moderate-or high-risk acute coronary
syndromes recommend an early invasive approach with concomitant antithrombotic therapy …

Summary Background In the HORIZONS-AMI trial, patients with acute ST-segment elevation
myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI) who …

Objectives: The aim of this meta-analysis was to compare the 30-day safety and efficacy of
bivalirudin with those of heparin with or without routine administration of a glycoprotein …

Background The comparative efficacy of various anticoagulation strategies has not been
clearly established in patients with acute myocardial infarction who are undergoing …

Objectives: This study was designed to determine the impact of bivalirudin on 1-year
outcomes in acute coronary syndrome (ACS) patients undergoing percutaneous coronary …

Importance The safety and efficacy of bivalirudin compared with heparin with or without
glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction (AMI) undergoing …

Background The aim of this study was to assess anticoagulation with the direct thrombin
inhibitor bivalirudin during percutaneous coronary intervention in individuals with moderate …

To assess the efficacy of the direct thrombin inhibitor bivalirudin relative to heparin during
contemporary coronary intervention, 1,056 patients who underwent elective or urgent …

Background Bivalirudin, as compared with heparin and glycoprotein IIb/IIIa inhibitors, has
been shown to reduce rates of bleeding and death in patients undergoing primary …